Evidence map›Paper›PMID 24720916›Full record

ReviewJACC. Heart failure2014

Developing therapies for heart failure with preserved ejection fraction: current state and future directions.

Javed Butler, Gregg C Fonarow, Michael R Zile, Carolyn S Lam, Lothar Roessig, Erik B Schelbert, Sanjiv J Shah, Ali Ahmed, Robert O Bonow, John G F Cleland and 22 more

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JACC. Heart failure, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05383287 (Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction), which is not on this map. Cited by 137 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 4 pooled it
24.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05383287 recruitingnot on this mapstarted 2022, after this paper: background citation

Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)

TypeobservationalSponsorManchester University NHS Foundation TrustRan2022 to 2029Enrolled1,250ConditionsHeart Failure With Preserved Ejection Fraction (HFpEF)
3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 4 syntheses or guidelines pooled it, 317 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Autonomic Neuromodulation Acutely Ameliorates Left Ventricular Strain in Humans.Journal of cardiovascular translational research · 2019
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 8 countries.

Javed ButlerDepartment of Medicine, Emory Cardiovascular Clinical Research Institute, Emory University, Atlanta, Georgia. Electronic address: javed.butler@emory.edu.
Gregg C FonarowDepartment of Medicine, University of California, Los Angeles, California.
Michael R ZileDivision of Cardiology, Medical University of South Carolina, and RHJ Department of Veterans Affairs Medical Center, Charleston, South Carolina.
Carolyn S LamCardiovascular Research Institute, National University Health System, Singapore.
Lothar RoessigGlobal Clinical Development, Bayer HealthCare AG, Wuppertal, Germany.
Erik B SchelbertDepartment of Medicine, University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania.
Sanjiv J ShahDepartment of Medicine, Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Ali AhmedDivision of Gerontology, University of Alabama at Birmingham, Birmingham, Alabama.
Robert O BonowDepartment of Medicine, Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
John G F ClelandDepartment of Cardiology, Castle Hill Hospital, Hull York Medical School, Kingston-Upon-Hull, England.
Robert J CodyCardiovascular & Metabolism Division, Janssen Pharmaceuticals, Raritan, New Jersey.
Ovidiu ChioncelInstitute of Emergency for Cardiovascular Diseases, Cardiology, Bucharest, Romania.
Sean P CollinsDepartment of Emergency Medicine, Vanderbilt University, Nashville, Tennessee.
Preston DunnmonCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Gerasimos FilippatosDepartment of Cardiology, Athens University Hospital, Attikon, Athens, Greece.
Martin P LefkowitzNovartis Pharmaceuticals Inc., East Hanover, New Jersey.
Catherine N MartiDepartment of Medicine, Emory Cardiovascular Clinical Research Institute, Emory University, Atlanta, Georgia.
John J McMurrayBritish Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland.
Frank MisselwitzGlobal Clinical Development, Bayer HealthCare AG, Wuppertal, Germany.
Savina NodariDivision of Cardiology, University of Brescia, Brescia, Italy.
Christopher O'ConnorDuke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
Marc A PfefferDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
Burkert PieskeDepartment of Cardiology, Medical University Graz, Graz, Austria.
Bertram PittDivision of Cardiology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan.
Giuseppe RosanoCentre for Clinical and Basic Science, San Raffaele-Roma, Rome, Italy.
Hani N SabbahDepartment of Medicine, Henry Ford Hospital, Detroit, Michigan.
Michele SenniCardiovascular Department, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Scott D SolomonDepartment of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
Norman StockbridgeCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
John R TeerlinkUniversity of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California.
Vasiliki V GeorgiopoulouDepartment of Medicine, Emory Cardiovascular Clinical Research Institute, Emory University, Atlanta, Georgia.
Mihai GheorghiadeDepartment of Medicine, Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Emory University · USNorthwestern University · USBayer (Germany) · DEBrigham and Women's Hospital · USUnited States Food and Drug Administration · USBrescia University · USBritish Heart Foundation · GBCastle Hill Hospital · GBClinical Emergency Hospital Bucharest · RODuke University · USHenry Ford Hospital · USJanssen (United States) · USMedical University of Graz · ATMedical University of South Carolina · USNational University Health System · SGNovartis (United States) · USOspedale Papa Giovanni XXIII · ITSan Francisco VA Medical Center · USUniversity General Hospital Attikon · GRUniversity of Alabama at Birmingham · US

Funding

Heart Failure Clinical Trials NetworkU10HL110302 · NHLBI · EMORY UNIVERSITY · PI SMITH, ANDREW · 2012 to 2018
$2.5M
NHLBI NIH HHS U10 HL110302
6 · The paper itself

Abstract

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.

Indexed as

AnimalsClinical Trials as TopicDiastoleDisease Models, AnimalEchocardiographyForecastingHeart AtriaHeart FailureHumansHypertension, PulmonaryStroke VolumeSystoleTreatment OutcomeVascular StiffnessVentricular Dysfunction, LeftVentricular Function, Leftepidemiologyheart failurepreserved ejection fractionprognosistreatment

Identifiers

PMID24720916
PMCPMC4028447
OpenAlexW1880552130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.